Complicated Intra Abdominal Infections Pipeline Insight
DelveInsight’s,“Complicated Intra-Abdominal Infections – Pipeline Insights, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Complicated Intra-Abdominal Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Complicated Intra-Abdominal Infections Understanding
Complicated Intra-Abdominal Infections: Overview
Complicated intra-abdominal infections (cIAI) are the infections that extend beyond the source organ into the peritoneal space as a result of perforation or other damage to the gastrointestinal tract. The disease is associated with either abscess formation or peritonitis. This type of infection is usually polymicrobial and is caused by Gram-negative aerobic bacteria, Gram-positive bacteria and anaerobic bacteria.
The symptoms of Complicated Intra-Abdominal Infections include:
- Abdominal pain and Abdominal fullness
- Nausea and vomiting
Complicated intra-abdominal infections (cIAI) diagnoses include intra-abdominal abscess, stomach or intestinal perforation, peritonitis, appendicitis, cholecystitis or diverticulitis along with physical assessment findings. Serum lactic acid, arterial blood gases, and oxygen saturation levels are usually tested, especially if sepsis is suspected. Moreover, radiographic images using CT scans with oral and intravenous contrast can also be useful for visualization of the abdominal cavity.
Complicated intra-abdominal infections (cIAI) can be treated with early detection, containment and appropriate antimicrobial treatment. Treatment is based on the severity of infection and whether the infection is community- or healthcare-acquired. There is a wide range of antimicrobial agents and combinations of agents available for use in complicated intra-abdominal infection. The widely used antimicrobial treatments are the combination of cefotaxime or ceftriaxone with metronidazole and monotherapy with amoxicillin/clavulanic acid. Because of widespread resistance of E. coli to ampicillin-sulbactam, this is no longer recommended for routine empiric therapy of complicated intra-abdominal infection. Increasing rates of infections caused by drug-resistant bacteria limit the effectiveness of currently available antibiotics.
Complicated Intra-Abdominal Infections Emerging Drugs Chapters
This segment of the Complicated Intra-Abdominal Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Complicated Intra-Abdominal Infections Emerging Drugs
- Sulopenem: Interim Therapeutics
Sulopenem is a novel agent that has demonstrated in vitro activity against gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Sulopenem is being evaluated in phase 3 clinical trials for complicated intra-abdominal infections. The USFDA has granted Special Protocol Agreements and Qualified Infectious Disease Product designations for Sulopenem.
- Avibactam/aztreonam: AbbVie
Aztreonam / Avibactam is a combination being investigated for treatment of complicated gram-negative bacterial infections. In the combination, Avibactam inhibits the serine-β-lactamases and allows Aztreonam to work against MBL-producing pathogens. In November 2019, The Food and Drug Administration has granted Qualified Infectious Disease Product (QIDP) designation and Fast Track designation to Aztreonam/Avibactam for the treatment of complicated intra-abdominal infections.
Further product details are provided in the report……..
Complicated Intra-Abdominal Infections: Therapeutic Assessment
This segment of the report provides insights about the different Complicated Intra-Abdominal Infections drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Complicated Intra-Abdominal Infections
There are approx. 15+ key companies which are developing the therapies for Complicated Intra-Abdominal Infections. The companies which have their Complicated Intra-Abdominal Infections drug candidates in the most advanced stage, i.e. phase III include, AbbVie.
DelveInsight’s report covers around 15+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Complicated Intra-Abdominal Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Complicated Intra-Abdominal Infections: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Complicated Intra-Abdominal Infections therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Complicated Intra-Abdominal Infections drugs.
- The companies and academics are working to assess challenges and seek opportunities that could influence Complicated Intra-Abdominal Infections R&D. The therapies under development are focused on novel approaches to treat/improve Complicated Intra-Abdominal Infections.
- In July 2019, Nosopharm and Evotec announced their partnership aiming at advancing Nosopharm’s lead candidate, NOSO-502, to the clinical stage, as well as developing a second-generation Odilorhabdin drug candidate.
Complicated Intra-Abdominal Infections Report Insights
- Complicated Intra-Abdominal Infections Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Complicated Intra-Abdominal Infections Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Complicated Intra-Abdominal Infections drugs?
- How many Complicated Intra-Abdominal Infections drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Complicated Intra-Abdominal Infections?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Complicated Intra-Abdominal Infections therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Complicated Intra-Abdominal Infections and their status?
- What are the key designations that have been granted to the emerging drugs?
- MerLion Pharmaceuticals
- Iterum Therapeutics
- Sulopenem etzadroxil